JiVitA-2: Newborn Vitamin A Supplementation Trial to Reduce Infant Mortality in Bangladesh

JiVitA-2 was a double-masked, cluster-randomized, 20,000-infant trial that was nested in the JiVitA-1 trial. It was designed to confirm the impact of newborn supplementation with 50,000 IU of vitamin A on reducing infant mortality through six months of age. 

A December 2006 DSMB review found newborn vitamin A receipt to be associated with a significant 15% reduction in infant mortality, leading the Board to recommend stopping the trial. Initial findings for both trials  (JiVitA-1 and JiVitA-2) were presented at the Micronutrient Forum in Turkey in April 2007.

Principal Investigator: Rolf Klemm (JHSPH)

Co-Principal Investigators:  Keith P. West, Jr. and Parul Christian (JHSPH)

Co-Investigators:

• Alain Labrique (JHSPH)
• Mahbubur Rashid (JiVitA, Bangladesh)
• Abu Ahmed Shamim (JiVitA, Bangladesh)
• Kerry Schulze (JHSPH)
• Christian Coles (JHSPH)
• Joanne Katz (JHSPH)
• Alfred Sommer (JHSPH)

Publications

Klemm RD, Labrique AB, Christian P, Rashid M, Shamim AA, Katz J, Sommer A, West KP Jr. (2008). Newborn Vitamin A Supplementation Reduced Infant Mortality in Rural Bangladesh. Pediatrics, 122, 1, e242-e250.

For more information on JiVitA-2, visit the JHSPH Center for Human Nutrition.